Beximco Pharmaceuticals (DHA:BXPHARMA) Net Change in Cash : BDT216 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Beximco Pharmaceuticals's Net Change in Cash for the three months ended in Mar. 2024 was BDT65 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was BDT216 Mil.

Beximco Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Beximco Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Net Change in Cash Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Change in Cash

Get a 7-Day Free Trial

216.76

24.52

40.45

194.71

-32.99

Beximco Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															373.88	-262.72	151.88	-	64.61

Beximco Pharmaceuticals Net Change in Cash Calculation

Beximco Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	6084.787	+	-2617.018	+	-3560.571	+	59.814
	=	-33

Beximco Pharmaceuticals's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 2131.026 + -344.369 + -1722.064 + 0.018

= 65

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT216 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » Net Change in Cash

Comparable Companies

DHA:BEACONPHAR DHA:RENATA DHA:ACMELAB DHA:ORIONINFU DHA:ASIATICLAB DHA:CENTRALPHL DHA:SQURPHARMA XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB BOM:532321 TSE:4507 HKSE:03692

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines